Beranda › Kanker Pankreas › Tennessee › Nashville
Uji klinis Kanker Pankreas di Nashville, TN
39 studi untuk Kanker Pankreas mencari peserta di lokasi sekitar Nashville (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Menerima pesertaFase 3
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology, Nashville
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Menerima pesertaFase 1
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Menerima pesertaFase 2
- SCRI Oncology Partners, Nashville
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Menerima pesertaFase 2
- SCRI Oncology Partners, Nashville
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Menerima pesertaFase 1
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
A Study of PHN-012 in Patients With Advanced Solid Tumors
Menerima pesertaFase 1
- PHN-012-001 Site, Nashville
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Menerima pesertaFase 1
- Sarah Cannon Research Institute, Nashville
DESTINY-PANTUMOUR04
Menerima pesertaStudi observasional
- Research Site, Nashville
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Menerima pesertaStudi observasional
- Vanderbilt University Medical Center, Nashville
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Menerima pesertaFase 2/3
- Henry-Joyce Cancer Clinic, Nashville
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Menerima pesertaFase 3
- SCRI Oncology Partners, Nashville
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Menerima pesertaFase 3
- Investigative Site US039, Nashville
- Investigative Site US060, Nashville
- Investigative Site US070, Nashville
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Menerima pesertaFase 1/2
- SCRI Oncology Partners, Nashville
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Menerima pesertaFase 1/2
- Sarah Cannon Research Institue, Nashville
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Menerima pesertaFase 1/2
- Tennessee Oncology, PLLC, Nashville
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Menerima pesertaFase 1
- Sarah Cannon Research Center, Nashville
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Menerima pesertaStudi observasional
- Vanderbilt University/Ingram Cancer Center, Nashville
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Menerima pesertaFase 2
- Sarah Cannon Research Institute, Nashville
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Menerima pesertaFase 1
- Vanderbilt - Ingram Cancer Center, Nashville
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Menerima pesertaFase 1
- Sarah Cannon Research Institute, Nashville
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1
- Investigative Site #102, Nashville
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
Menerima pesertaFase 2
- Vanderbilt-Ingram Cancer Center, Nashville
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Menerima pesertaFase 2
- SCRI Oncology Partners, Nashville
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Menerima pesertaFase 1
- Sarah Cannon, SCRI Oncology Partners, Nashville
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Menerima pesertaFase 1/2
- Vanderbilt University Medical Center, Nashville
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Menerima pesertaFase 1
- Research Site, Nashville
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Menerima pesertaFase 1
- Sarah Cannon Research Institute, Nashville
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Menerima pesertaFase 1/2
- Sarah Cannon Research Institute, Nashville
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Menerima pesertaFase 1/2
- Sarah Cannon Research Institute, Nashville
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Menerima pesertaFase 1/2
- SCRI Oncology Partners, Nashville
Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
Menerima pesertaStudi observasional
- Veterans Affairs Medical Center - Nashville, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
Disposable Perfusion Phantom for Accurate DCE (Dynamic Contrast Enhanced)-MRI Measurement of Pancreatic Cancer Therapy Response
Menerima peserta
- Vanderbilt University Medical Center, Nashville
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Menerima pesertaFase 2
- Ohio State University-Telemedicine, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Vanderbilt-Ingram Cancer Center, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Nashville
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Menerima pesertaFase 1/2
- Tennessee Oncology, Nashville
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Menerima pesertaFase 1
- Exelixis Clinical Site #6, Nashville
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Menerima pesertaFase 1
- Vanderbilt University Medical Center, Nashville
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Menerima pesertaFase 1/2
- SCRI Oncology Partners, Nashville
Uji klinis Kanker Pankreas di kota lain
- Houston, TX61 studi
- New York City, NY60 studi
- Boston, MA43 studi
- Los Angeles, CA35 studi
- St. Louis, MO33 studi
- Arlington, VA33 studi
- Baltimore, MD31 studi
- San Antonio, TX31 studi
- Philadelphia, PA26 studi
- Tampa, FL26 studi
- Durham, NC24 studi
- San Diego, CA24 studi
Studi lain di Nashville
- Kanker Paru Non-Sel Kecil97 studi
- Kanker Payudara81 studi
- Kanker Metastatik70 studi
- Kanker Kolorektal69 studi
- Kanker (semua jenis)65 studi
- Kanker Ovarium49 studi
- Kanker Prostat43 studi
- Kanker Paru40 studi
- Karsinoma Sel Skuamosa Kepala dan Leher39 studi
- Kanker Endometrium38 studi
- Melanoma33 studi
- Mieloma Multipel32 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.